Castellum, Inc. (CTM) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Castellum, Inc. is a technology company focused on cybersecurity, information technology, electronic warfare, and information operations, primarily serving U.S. government agencies, financial services, and healthcare sectors. The company operates as a single reporting segment delivering products and services across defense, federal, civilian, and commercial markets.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $11.61 million | $11.74 million | $34.47 million | $34.15 million |
| Gross Profit | $4.96 million | $4.84 million | $14.15 million | $14.09 million |
| Gross Margin | 42.7% | 41.2% | 41.1% | 41.2% |
| Net Loss | $(1.31) million | $(9.22) million | $(7.33) million | $(15.70) million |
| Operating Cash Flow | N/A | N/A | $1.51 million | $(3.14) million |
| Cash & Equivalents | $2.74 million (as of Sept 30, 2024) | |||
| Total Debt (Current + Non-Current) | ~$10.8 million (Notes Payable + Revolver) |
Material Changes vs. Prior Period
- Profitability Improvement: The Net Loss for Q3 2024 decreased significantly to $1.31 million compared to $9.22 million in Q3 2023. This improvement is primarily attributed to the absence of a $6.92 million goodwill impairment loss recorded in Q3 2023.
- Revenue Stability: Q3 revenue remained relatively flat, declining slightly by 1% year-over-year due to lost positions on legacy contracts. YTD revenue increased 1% driven by organic contributions from the Global Technology and Management Resources (GTMR) acquisition.
- Operating Expenses: Total operating expenses decreased 53% in Q3 2024 compared to Q3 2023, largely due to the non-recurring impairment charge in the prior year. YTD operating expenses decreased 32% due to reduced stock-based compensation and the absence of the impairment loss.
- Cash Flow Turnaround: Operating cash flow turned positive, providing $1.51 million in the first nine months of 2024, compared to a usage of $3.14 million in the same period in 2023.
Guidance, Outlook, and Risks
- Backlog: As of September 30, 2024, total scheduled backlog is $87.6 million (including $15.5 million funded). Including unscheduled options, the grand total backlog is $116.0 million. Management expects to recognize approximately 38% of remaining performance obligations over the next 12 months.
- Liquidity & Capital: The company raised approximately $2.2 million in net proceeds from a registered direct offering in January 2024. In February 2024, a new $4.0 million revolving credit facility with Live Oak Bank was established (later modified to a $2.0 million capacity in August 2024). As of period end, unused borrowing capacity was approximately $470,000.
- Divestiture: The company sold its subsidiary, Mainnerve Federal Services, Inc. (MFSI), in September 2024, recording a gain of $39,234. Future consideration is tied to 6% of MFSI revenue until 2029.
- Risks:
- Government Funding: Reliance on U.S. government spending creates risks related to budget deficits, continuing resolutions, and potential sequestration.
- Self-Insurance: The company began self-insuring employee health benefits in June 2024, exposing it to potential unexpected costs if claims exceed estimates.
- Debt Obligations: Significant debt maturities and interest payments are scheduled through 2026, requiring ongoing liquidity management.
Investor Verification Checklist
- Debt Maturity Profile: Verify the specific repayment schedules for the $6.0 million Eisiminger Note and the $2.4 million Buckhout Note maturing in 2026.
- Backlog Conversion: Monitor the conversion rate of the $19.0 million unfunded backlog into revenue, given the reliance on annual Congressional appropriations.
- Self-Insurance Reserves: Review future filings for the adequacy of the $79,217 self-insurance reserve established in Q3 2024 against actual claims experience.
- Customer Concentration: Note that three customers represented 52% of revenue for the nine months ended September 30, 2024.
- Equity Dilution: Track the exercise of 8.4 million regular warrants issued in the January 2024 offering, which have an exercise price of $0.35.